<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384395</url>
  </required_header>
  <id_info>
    <org_study_id>14-0549</org_study_id>
    <nct_id>NCT02384395</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection</brief_title>
  <acronym>PHI 05</acronym>
  <official_title>IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, single arm, 96-week open-label study of the safety and virologic
      efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC)
      initiated during acute HIV infection (AHI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at the University of North Carolina in Chapel Hill, NC and Duke
      University in Durham, NC. All forty (40) participants will be enrolled for 96 weeks and will
      receive DTG/3TC/ABC FDC.

      We propose to evaluate the efficacy and time to viral suppression with DTG/3TC/ABC FDC as
      initial therapy for AHI (acute HIV infection), as well as the feasibility of prompt
      administration using a rapid HLA-B57 (human leukocyte antigen) screening antibody assay. In
      addition to validating the restriction of RCI (resting cell infection) by ART (antiretroviral
      therapy) including a DTG-based regimen initiated during AHI, we will seek correlations
      between low RCI, residual GALT (gastrointestinal associated lymphoid tissue) HIV expression,
      and measures of immune activation. We hypothesize that rapid reduction in plasma viremia with
      this regimen will limit the area under the pre-ART viral load curve, and thus reduce the
      latent reservoir size as measured by a viral outgrowth assay one to two years following ART
      start, and as compared with the latent reservoir size in acutely infected individuals started
      on regimens without an integrase inhibitor based regimen. In addition, we will examine the
      longitudinal impact of the proposed integrase-based regimen initiated during the acute period
      on immune activation through week 96. If residual viral expression and persistent immune
      dysfunction is related to the burden of the latent viral reservoir (and presumably its
      periodic activation) these abnormalities should be ameliorated by early ART with rapid viral
      suppression. Finally, we will evaluate dolutegravir levels in plasma and GALT and whether
      rapid viral suppression with the proposed dolutegravir-based ART regimen impacts HIV RNA
      levels in GALT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load measurement of &lt;200 copies/mL</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Grade 3 or higher adverse event (AE)</measure>
    <time_frame>baseline through week 96</time_frame>
    <description>sign/symptom, lab toxicity, or clinical events, or Grade 1 or higher AE that is definitely, probably, or possibly related to study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic efficacy of DTG/3TC/ABC FDC given once daily to participants with acute HIV as determined by the proportion of treated participants with HIV-1 RNA to &lt;50 copies/mL</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of virologic decline in the first 24 weeks of treatment</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV</condition>
  <condition>Acute HIV Infection</condition>
  <arm_group>
    <arm_group_label>DTG/3TC/ABC FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir (DTG 50 mg), abacavir sulfate (ABC 600 mg) and lamivudine (3TC 300 mg) formulated in a single tablet fixed dose combination (FDC) (DTG/ABC/3TC, GSK2619619), administered orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG/3TC/ABC FDC</intervention_name>
    <description>DTG/3TC/ABC FDC as initial therapy for AHI</description>
    <arm_group_label>DTG/3TC/ABC FDC</arm_group_label>
    <other_name>Dolutegravir</other_name>
    <other_name>abacavir sulfate</other_name>
    <other_name>lamivudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Documentation of Acute HIV infection at or within 30 days of study entry.

          2. Men and women age ≥18 years.

          3. ART naive, defined as ≤14 days of antiretroviral treatment at any time prior to entry.
             The only exceptions are:

               -  Pre-exposure prophylaxis (PrEP) and documented as HIV-1 negative at least 1 month
                  prior to AHI diagnosis during PrEP, and

               -  Post-exposure prophylaxis (PEP) provided the participant was documented as HIV-1
                  negative at least 3-6 months following completion of PEP treatment.

          4. Lab values obtained within 30 days prior to study entry:

               -  Absolute neutrophil count &gt;500/mm3

               -  Hemoglobin &gt; 8.5 g/dL for men and &gt; 8.0 g/dL for women

               -  Platelet count &gt;50,000/mm3

               -  Lipase ≤ 3 X upper limit of normal (ULN), single repeat test is allowed to
                  determine eligibility

               -  Calculated creatinine clearance (Cockcroft-Gault formula) ≥ 50mL/min:

             CrCl = (140-age) x body weight (kg) (x 0.85 if female) Serum creatinine [mg/dL] x (72)

          5. Testing for HBsAg is pending. Note: Participants who test positive for HBsAg will be
             terminated from the study prior to starting study treatment.

          6. Testing for HLA-B57 and/or HLA-B*5701 is pending. Note: Participants who test positive
             for HLA-B*5701 will be terminated from the study prior to starting study treatment.

          7. A female is eligible to enter and participate in the study if she:

               -  Is of non-childbearing potential defined as either post-menopausal (12 months of
                  spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming
                  pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy;
                  or,

               -  Is of child-bearing potential, with a negative pregnancy test at screening and at
                  enrollment, who agrees to use one of the methods of contraception listed below.

               -  Complete abstinence from intercourse from 2 weeks prior to administration of
                  study medication, throughout the study, and for at least 2 weeks after
                  discontinuation of all study medication;

               -  Double barrier method (male condom/spermicide, male condom/diaphragm,
                  diaphragm/spermicide);

               -  Approved hormonal contraception - used alone is not considered a sufficient form
                  of contraception for the study see Protocol Appendix 1 for a listing of examples
                  of approved hormonal contraception;

               -  Any intrauterine device (IUD) with published data showing that the expected
                  failure rate is &lt;1% per year; see Protocol Appendix 2 for a listing of IUDs
                  meeting this criterion;

               -  Male partner sterilization confirmed prior to the female participant's entry into
                  the study, and this male is the sole partner for that patient;

               -  Any other method with published data showing that the expected failure rate is
                  &lt;1% per year.

               -  Any contraception method must be used consistently, in accordance with the
                  approved product label and for at least 2 weeks after discontinuation of the
                  study medication.

          8. Ability and willingness of participant to give written informed consent.

        Exclusion Criteria

          1. ALT ≥ 5 times Upper Limit of Normal (≥5xULN)

          2. AST ≥ 3x ULN

          3. Bilirubin ≥1.5x ULN (with &gt;35% direct bilirubin)

          4. Women who are breast-feeding.

          5. Women with a positive pregnancy test on enrollment or prior to study drug
             administration.

          6. History or presence of allergy to the study drugs or their components.

          7. Requires or is anticipated to require any of the prohibited concomitant therapy:
             barbiturates, dofetilide, modafinil, oxcarbazepine, pioglitazone, pimozide, rifampin,
             rifapentine, phenytoin, phenobarbital, carbamazepine, and St. John's wort.

               -  Dofetilide is prohibited, as DTG may inhibit its renal tubular secretion
                  resulting in increased dofetilide concentrations and potential for toxicity.

          8. Unable to discontinue any current medications that are excluded during study
             treatment.

          9. Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), radiation
             therapy, HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy
             within 30 days prior to study entry.

               -  Prednisone at a daily dose of 10 mg or less (physiologic replacement dose) is
                  permitted.

         10. Treatment with radiation therapy or cytotoxic chemotherapeutics agents within 28 days
             prior to screening or has an anticipated need for these agents during the study.

         11. Administration of an HIV-1 immunotherapeutic vaccine within 90 days prior to
             screening.

         12. Prior treatment with any other experimental drug for any indication (within 30 days of
             initiating study treatment).

         13. Difficulty swallowing capsules/tablets.

         14. Inability to communicate effectively with study personnel.

         15. Incarceration; prisoner recruitment and participation are not permitted.

         16. Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements or confound the
             analysis of study endpoints.

         17. Any condition (including but not limited to alcohol and drug use) or any active
             clinically significant disease or findings during screening of medical history or
             physical examination, which, in the opinion of the Investigator would interfere with
             patient safety or compliance.

         18. Serious illness requiring systemic treatment and/or hospitalization until patient
             either completes therapy or is clinically stable on therapy, in the opinion of the
             site investigator, for at least 7 days prior to study entry.

             NOTE: Oral candidiasis, vaginal candidiasis, mucocutaneous herpes simplex, and other
             minor illnesses (as judged by the site investigator) have no restriction.

         19. A life expectancy less than twelve months.

         20. Acute viral hepatitis, including, but not limited to, hepatitis A, B, or C.

         21. History of myocardial infarction or diagnosis of coronary artery disease.

         22. History of ongoing or clinically relevant pancreatitis within the previous 6 months.

         23. Chronic hepatitis C infection with an anticipated need for treatment during the study
             period (through week 96).

         24. Chronic hepatitis B infection (see inclusion criteria 5).

         25. Evidence for moderate to severe hepatic impairment (as defined by the presence of
             cirrhosis, ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or
             gastric varices, persistent jaundice or Child-Pugh class B or greater hepatic
             impairment).

         26. Evidence of biliary abnormalities (with the exception of Gilbert's syndrome or
             asymptomatic gallstones).

         27. Any verified grade 4 laboratory abnormality with exception of ALT as defined in
             exclusion criteria 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cindy Gay, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JoAnn Kuruc, MSN, RN</last_name>
    <phone>919-966-8533</phone>
    <email>joann_kuruc@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristen Hancock, RN</last_name>
    <phone>919-843-6848</phone>
    <email>kristen_hancock@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara McGee, MSPH, PA-C</last_name>
      <phone>919-668-0242</phone>
      <email>kara.mcgee@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Mehri McKellar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.unc.edu</url>
    <description>University of North Carolina website</description>
  </link>
  <reference>
    <citation>Adolescents. PoAGfAa. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. In: Department of Health and Human Servies.; 2013</citation>
  </reference>
  <reference>
    <citation>Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999 Sep;104(6):R13-8.</citation>
    <PMID>10491418</PMID>
  </reference>
  <reference>
    <citation>Pilcher CD, Eron JJ Jr, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest. 2004 Apr;113(7):937-45. Review. Erratum in: J Clin Invest. 2006 Dec;116(12):3292.</citation>
    <PMID>15057296</PMID>
  </reference>
  <reference>
    <citation>Pires A, Hardy G, Gazzard B, Gotch F, Imami N. Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):783-90.</citation>
    <PMID>15213561</PMID>
  </reference>
  <reference>
    <citation>Ramratnam B, Ribeiro R, He T, Chung C, Simon V, Vanderhoeven J, Hurley A, Zhang L, Perelson AS, Ho DD, Markowitz M. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):33-7.</citation>
    <PMID>14707789</PMID>
  </reference>
  <reference>
    <citation>Chamberland A, Sylla M, Boulassel MR, Baril JG, Côté P, Thomas R, Trottier B, Rouleau D, Routy JP, Tremblay C; Investigators of the Primary HIV-Infection Cohort of Montreal. Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection. Int J STD AIDS. 2011 Mar;22(3):146-50. doi: 10.1258/ijsa.2010.010292.</citation>
    <PMID>21464451</PMID>
  </reference>
  <reference>
    <citation>Gay CL, Mayo AJ, Mfalila CK, Chu H, Barry AC, Kuruc JD, McGee KS, Kerkau M, Sebastian J, Fiscus SA, Margolis DM, Hicks CB, Ferrari G, Eron JJ; Duke-UNC Acute HIV Infection Consortium. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011 Apr 24;25(7):941-9. doi: 10.1097/QAD.0b013e3283463c07.</citation>
    <PMID>21487250</PMID>
  </reference>
  <reference>
    <citation>Cossarini F, Boeri E, Canducci F, Salpietro S, Bigoloni A, Galli L, Spagnuolo V, Castagna A, Clementi M, Lazzarin A, Gianotti N. Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):e51-4. doi: 10.1097/QAI.0b013e3181fcc0f1.</citation>
    <PMID>21233631</PMID>
  </reference>
  <reference>
    <citation>Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):350-6. doi: 10.1097/QAI.0b013e3181b064b0.</citation>
    <PMID>19648823</PMID>
  </reference>
  <reference>
    <citation>Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.</citation>
    <PMID>21412057</PMID>
  </reference>
  <reference>
    <citation>Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, Cohen MS, Coffin JM, Bosch RJ, Gay CL, Eron JJ, Margolis DM, Perelson AS. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9523-8. doi: 10.1073/pnas.1120248109. Epub 2012 May 29.</citation>
    <PMID>22645358</PMID>
  </reference>
  <reference>
    <citation>Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, Lennox JL, Margolis DM, Hicks CB, Eron JJ. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):505-8. doi: 10.1097/QAI.0b013e318285cd33.</citation>
    <PMID>23314410</PMID>
  </reference>
  <reference>
    <citation>Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287. Erratum in: J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e120. Dosage error in article text.</citation>
    <PMID>20404738</PMID>
  </reference>
  <reference>
    <citation>Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4. Epub 2013 Jan 8.</citation>
    <PMID>23306000</PMID>
  </reference>
  <reference>
    <citation>Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003 Jun;9(6):727-8. Epub 2003 May 18.</citation>
    <PMID>12754504</PMID>
  </reference>
  <reference>
    <citation>Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, Bandarenko N, Schmitz JL, Bosch RJ, Landay AL, Coffin JM, Margolis DM. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. 2008 Jun 19;22(10):1131-5. doi: 10.1097/QAD.0b013e3282fd6df4.</citation>
    <PMID>18525258</PMID>
  </reference>
  <reference>
    <citation>Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 2010 Feb 23;5(2):e9390. doi: 10.1371/journal.pone.0009390.</citation>
    <PMID>20186346</PMID>
  </reference>
  <reference>
    <citation>Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, Collier AC, Corey L, Fauci AS. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis. 2007 Jun 15;195(12):1762-4. Epub 2007 May 2.</citation>
    <PMID>17492591</PMID>
  </reference>
  <reference>
    <citation>Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7.</citation>
    <PMID>9371822</PMID>
  </reference>
  <reference>
    <citation>Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997 May 8;387(6629):183-8.</citation>
    <PMID>9144289</PMID>
  </reference>
  <reference>
    <citation>Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol. 1994 Mar;32(3):732-9.</citation>
    <PMID>8195386</PMID>
  </reference>
  <reference>
    <citation>Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19;366(9485):549-55.</citation>
    <PMID>16099290</PMID>
  </reference>
  <reference>
    <citation>Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, Baker D, Bloch M, Murray JM, Zaunders J, Emery S, Cooper DA, Kelleher AD; PINT study team. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS. 2011 Nov 13;25(17):2069-78. doi: 10.1097/QAD.0b013e32834b9658. Erratum in: AIDS. 2012 Nov 28;26(18):2425. AIDS. 2012 Jul 17;26(11):1455.</citation>
    <PMID>21860347</PMID>
  </reference>
  <reference>
    <citation>Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, Lopez P, Shet A, Low A, Mohri H, Boden D, Racz P, Markowitz M. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 2006 Dec;3(12):e484. Erratum in: PLoS Med. 2006 Dec;3(12):e546.</citation>
    <PMID>17147468</PMID>
  </reference>
  <reference>
    <citation>Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, McGowan I, Brown S, Anton PA. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr. 2006 Sep;43(1):65-8.</citation>
    <PMID>16936559</PMID>
  </reference>
  <reference>
    <citation>Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012 Jun 30;379(9835):2439-48. doi: 10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug 25;380(9843):730.</citation>
    <PMID>22748591</PMID>
  </reference>
  <reference>
    <citation>Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.</citation>
    <PMID>18650512</PMID>
  </reference>
  <reference>
    <citation>Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL; Study 145 Team. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18.</citation>
    <PMID>22015077</PMID>
  </reference>
  <reference>
    <citation>Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85. doi: 10.1097/QAI.0b013e31828ace69.</citation>
    <PMID>23412015</PMID>
  </reference>
  <reference>
    <citation>Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, Gallant JE, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J; GS-US-236-0102 Study Team. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100. doi: 10.1097/QAI.0b013e318289545c.</citation>
    <PMID>23392460</PMID>
  </reference>
  <reference>
    <citation>Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY; QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011 Dec;11(12):907-15. doi: 10.1016/S1473-3099(11)70196-7. Epub 2011 Sep 18. Erratum in: Lancet Infect Dis. 2011 Dec;11(12):895. Dosage error in article text.</citation>
    <PMID>21933752</PMID>
  </reference>
  <reference>
    <citation>German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010 Nov;55(3):323-9. doi: 10.1097/QAI.0b013e3181eb376b.</citation>
    <PMID>20683270</PMID>
  </reference>
  <reference>
    <citation>Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010 Mar 15;201(6):814-22. doi: 10.1086/650698.</citation>
    <PMID>20146631</PMID>
  </reference>
  <reference>
    <citation>Schrijvers R, Debyser Z. Quad's in it for antiretroviral therapy? Lancet. 2012 Jun 30;379(9835):2403-5. doi: 10.1016/S0140-6736(12)61029-0.</citation>
    <PMID>22748575</PMID>
  </reference>
  <reference>
    <citation>Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.</citation>
    <PMID>18650513</PMID>
  </reference>
  <reference>
    <citation>DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012 Jun 30;379(9835):2429-38. doi: 10.1016/S0140-6736(12)60918-0.</citation>
    <PMID>22748590</PMID>
  </reference>
  <reference>
    <citation>Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011 Sep 10;25(14):1737-45. doi: 10.1097/QAD.0b013e32834a1dd9.</citation>
    <PMID>21716073</PMID>
  </reference>
  <reference>
    <citation>Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010 Jan;54(1):254-8. doi: 10.1128/AAC.00842-09. Epub 2009 Nov 2.</citation>
    <PMID>19884365</PMID>
  </reference>
  <reference>
    <citation>Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother. 2010 Dec;65(12):2485-8. doi: 10.1093/jac/dkq350. Epub 2010 Sep 18. Review.</citation>
    <PMID>20852268</PMID>
  </reference>
  <reference>
    <citation>Song I, Borland J, Chen S, Patel P, Wajima T, Peppercorn A, Piscitelli SC. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012 Mar;56(3):1627-9. doi: 10.1128/AAC.05739-11. Epub 2011 Dec 19.</citation>
    <PMID>22183173</PMID>
  </reference>
  <reference>
    <citation>Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):393-8. doi: 10.1097/QAI.0000000000000193.</citation>
    <PMID>24798770</PMID>
  </reference>
  <reference>
    <citation>Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S; extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013 Nov;13(11):927-35. doi: 10.1016/S1473-3099(13)70257-3. Epub 2013 Sep 25.</citation>
    <PMID>24074642</PMID>
  </reference>
  <reference>
    <citation>Walmsley SL, Berenguer J, Kuong-Josses M-A, Kilby JM, Lutz T, Podzamczer D, et al. Dolutegravir Regimen Statistically Superior to Efavirenz/Tenofovir/Emtricitabine: 96-Week Results From the SINGLE Study (ING114467) In: 21st Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2014.</citation>
  </reference>
  <reference>
    <citation>Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Erratum in: Lancet. 2014 Jan 4;383(9911):30.</citation>
    <PMID>23830355</PMID>
  </reference>
  <reference>
    <citation>Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM; VIKING-3 Study Group. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014 Aug 1;210(3):354-62. doi: 10.1093/infdis/jiu051. Epub 2014 Jan 19.</citation>
    <PMID>24446523</PMID>
  </reference>
  <reference>
    <citation>Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1. Erratum in: Lancet. 2015 Jun 27;385(9987):2576.</citation>
    <PMID>24698485</PMID>
  </reference>
  <reference>
    <citation>Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541.</citation>
    <PMID>24195548</PMID>
  </reference>
  <reference>
    <citation>Pilcher CD, Fiscus SA, Nguyen TQ, Foust E, Wolf L, Williams D, Ashby R, O'Dowd JO, McPherson JT, Stalzer B, Hightow L, Miller WC, Eron JJ Jr, Cohen MS, Leone PA. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005 May 5;352(18):1873-83.</citation>
    <PMID>15872202</PMID>
  </reference>
  <reference>
    <citation>D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2. Erratum in: Lancet. 2008 Jul 26;372(9635):292.</citation>
    <PMID>18387667</PMID>
  </reference>
  <reference>
    <citation>Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep. 2010 Aug;7(3):127-33. doi: 10.1007/s11904-010-0047-3. Review.</citation>
    <PMID>20521126</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dolutegravir</keyword>
  <keyword>Abacavir</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>acute HIV infection</keyword>
  <keyword>human leukocyte antigen</keyword>
  <keyword>latent HIV reservoir</keyword>
  <keyword>integrase-based regimen</keyword>
  <keyword>viremia</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>fixed dose combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

